Calidi Biotherapeutics (CLDI) Return on Capital Employed (2022 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Return on Capital Employed of 269.58% for Q4 2025, up 208841.0% year-over-year from N/an in Q4 2024, and up 11.54% quarter-over-quarter from 304.76% in Q3 2025.
Calidi Biotherapeutics (CLDI) Return on Capital Employed (2022 - 2026) Analysis & Trends
Calidi Biotherapeutics' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 269.58% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 208841.0% year-over-year to 269.58%; the TTM figure through Dec 2025 stood at 269.58% (up 208841.0% YoY), while the FY2025 annual figure was 266.86%, up 56923.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 269.58%, up from 304.76% in the prior quarter.
- The five-year high for Return on Capital Employed was 634.05% in Q4 2023, with the low at 2357.99% in Q4 2024.
- The 4-year median for Return on Capital Employed is 107.24% (2023), against an average of 123.7%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 299204 bps in 2024, then jumped 208841 bps in 2025.
- Calidi Biotherapeutics' Return on Capital Employed stood at 60.96% in 2022, then soared by 940 bps to 634.05% in 2023, then plunged by 472 bps to 2357.99% in 2024, then jumped by 89 bps to 269.58% in 2025.
- Business Quant data shows CLDI's Return on Capital Employed at 269.58% in Q4 2025, 304.76% in Q3 2025, and 291.46% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | -403.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -403.21% |
| Dec 31, 2025 | -269.58% |
| Sep 30, 2025 | -304.76% |
| Jun 30, 2025 | -291.46% |
| Mar 31, 2025 | -218.40% |
| Dec 31, 2024 | -2,357.99% |
| Sep 30, 2024 | 547.57% |
| Jun 30, 2024 | 481.99% |
| Mar 31, 2024 | 485.98% |
| Dec 31, 2023 | 634.05% |
| Sep 30, 2023 | -202.51% |
| Jun 30, 2023 | -66.72% |
| Mar 31, 2023 | -107.24% |
| Dec 31, 2022 | 60.96% |